



Recurrent severe symptomatic hyponatraemia induced by low-dose oral cyclophosphamide in a patient with ANA-related vasculitis.

Dineen R¹, Pazderska A¹, Mullan R², Gibney J¹, Sherlock M¹

1. Department of Endocrinology 2. Department of Rheumatology,
Adelaide and Meath Hospital incorporating the National Children's Hospital, Tallaght, Dublin, Ireland

Introduction

- ❖ Cyclophosphamide is an alkylating agent used in the treatment of malignant and autoimmune diseases.
- ❖ Severe hyponatraemia is a serious electrolyte disorder with life threatening neurological sequelae.
- ❖ It has been reported in association with a variety cytotoxic agents as vinca alkaloids, platinum compounds and alkylating agents.¹
- ❖ Severe hyponatraemia after administration of low-dose cyclophosphamide therapy (<15 mg/kg) is extremely rare.

Clinical Presentation


- ❖ 61 year old lady commenced on intravenous cyclophosphamide for mononeuritis multiplex

Medical History:

- ❖ ANA positive systemic vasculitis
- ❖ Sjogrens syndrome
- ❖ Osteoarthritis
- ❖ Multinodular Goitre

First Cycle- May 2014

- Low dose cyclophosphamide, 620mg (12.5mg/kg).
- Oral mesna pre & post infusion.
- Oral Ondansetron 8mg pre & post infusion.
- Prehydration ; 1L 0.9% saline
3L of H₂O to prevent haemorrhagic cystitis.



Investigations


Serum Osmolality	240mOsm/kg
Urine Osmolality	347 mOsm/kg
Urinary Sodium	121mmol/L
8am Cortisol	800nmol/l
FT4	15.4pmol/l
TSH	1.04mIU/L

Management

- ❖ 24hrs post infusion, at a serum sodium of 116mmol/L, she was nauseous, drowsy and slurring her speech.
- ❖ She was transferred to ITU.
- ❖ Given stat dose of 100ml of 3% saline.
- ❖ Her sodium rose from 115mmol/L to 118mmol/L.
- ❖ Persistent clinical evidence of cerebral irritation hence given another 100ml of 3% saline.
- ❖ Serum sodium rise 118mmol/l to 120mmol/l.
- ❖ Within 48hrs her serum sodium rose to 125mmol/L.
- ❖ She recovered without any neurological deficits.

Second Cycle- June 2014

- Low dose cyclophosphamide,
- Reduced Prehydration; NO IV saline, Consumed 2L of H₂O.



- 12hrs post infusion, her serum sodium fell to 121mmol/l without neurological symptoms
- Placed on fluid restriction of 1.5L with gradual rise in serum sodium

Third Cycle- July 2014

- Low dose cyclophosphamide
- NO prehydration
- 1.5L fluid restriction
- Fall in serum sodium from 135mmol/L to 129mmol/l
- No neurological symptoms
- Spontaneous correction

Conclusion

- ❖ Patients receiving cyclophosphamide are at high risk of developing symptomatic hyponatraemia due to SIADH even at low doses of therapy.
- ❖ Cyclophosphamide may induce SIADH, by potentiating the renal actions of AVP².
- ❖ The combination of both increased ADH effect and excess water intake to prevent haemorrhagic cystitis can induce potentially life-threatening hyponatraemia³.
- ❖ Clinicians need to be aware of this threat when encouraging large volume prehydration and diuresis with cyclophosphamide therapy.
- ❖ It is possible that pre-hydration with isotonic saline rather than oral water may minimise the incidence of this complication

References

- Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer. 1996 Sep;4(5):341-50
- Lee YC, Park JS, Lee CH, et al. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transplant 25: 1520-4, 2010.
- McCarron M, Wright GD, Roberts SD. Water intoxication after low dose cyclophosphamide. BMJ 311: 292, 1995

